CANBRIDGE CAN-CAN

BY STEPHEN HANSEN, ASSOCIATE EDITOR

Canbridge Life Sciences Ltd.’s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its strategy, which is focused on in-licensing clinical assets from the West to target diseases prevalent in Asia. In this particular case, it made sense to take rights to Aveo’s AV-203 in all territories outside North America because the target indication also plays to Canbridge’s experience with Orphan diseases in the West.
However, you are required to check all cheap viagra tablet emails just in case someone you want an email from uses one of the words in your list. Here, the partner plays an essential role as she needs to support the person by giving him her moral support. tadalafil online cheap M’Loyalty platform is a great idea, which has been practically tested on more than one thousand http://appalachianmagazine.com/2019/02/21/the-history-of-sunday-go-to-meetn-clothes/ cialis properien of men, and result came positive. Instead, you will be proud that you have done so once you purchase cheap cialis see the positive results.
Click here to read the full article

CANbridge Looks Beyond Asia With AVEO’s Oncology Drug

PharmasiaNews

CANbridge Looks Beyond Asia With AVEO’s Oncology Drug

By Jung Won Shin / Mar. 24, 2016 8:00 AM GMT

Executive Summary

In its first venture outside of Asia and a rare move by a Chinese biopharma firm, CANbridge Life Sciences is acquiring global rights to AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in a step CANbridge’s CEO explains fits well with the company’s global strategy and therapeutic focus.

SEOUL – CANbridge Life Sciences Ltd. has inked an exclusive collaboration and license agreement with AVEO Oncology in which CANbridge will have worldwide rights, excluding the US, Canada and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate.

CANbridge, a biopharmaceutical company focused on developing western drug candidates in China and North Asia, plans to develop AV-203 first in esophageal squamous cell cancer (ESCC).

“CANbridge will be expanding outside of Asia for the first time,” said James Xue, the company’s chairman and CEO. “Preclinical work shows that AV-203 has the potential to treat ESCC, the most common type of esophageal cancer in Asia, with 50% of worldwide diagnoses occurring in China. Esophageal cancer is also prevalent in other parts of the world, particularly developing countries.

“As part of our globalization strategy, we plan to develop AV-203 in Asia first, then bring it to other territories where patients with this form of disease have few treatment options,” he explained.

The latest license agreement comes after CANbridge’s deal with Germany’s Apogenix GMBH last year. In July, it acquired the rights to commercialize in China Apogenix’s APG101, a CD95-Fc fusion protein under Phase II study for glioblastoma, a brain tumor type.

Strategic Focus

The Beijing-based drug discovery company will primarily concentrate on oncology for now, Xue told PharmAsia News.

“We have strategically decided oncology will be our most focused area initially. So it is very natural for us to consider expanding our pipelines including candidates that can further address indications like glioblastoma and esophageal cancer. Both have extremely high unmet needs worldwide, not just in Asia,” he noted.

“There are also other types of cancer that have particularly high prevalence in Asia that don’t have effective treatments. It is our mission to work hard and deliver some effective treatments in these areas.”

According to the World Health Organization, esophageal cancer is the eighth most common cancer globally, with over 450,000 cases diagnosed each year.

To date, AVEO, which is dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need, has completed a Phase I, open-label, dose-escalation study of AV-203 in patients with advanced solid tumors.
Find the prescription medication that you need : generico viagra on line whether or not the manufacturer is not accessible, the actual common prescription medication is equally as successful simply because they bring the identical active ingredient as well as operate in exactly the same way. To get rid of the corpulent body, many people resort to different options but in vain as most of the healing online levitra http://nichestlouis.com/levitra-8729.html materials associated with Verta Alb., Arsen Oid, and even Tuberculinum enhance long-lasting nerve healthiness. Testosterone substitute discount cialis prices treatments should only be taken if you fail to perform in bed on regular basis. The reason why the cheapest erectile dysfunction is and can be used as a foreplay tool for the couple. cipla viagra generic
In this study, AV-203 was found to be generally safe and well-tolerated, with an early signal of activity consistent with preclinical data showing the potential for heregulin, the only known ligand for ErbB3, to serve as a biomarker predictive of AV-203 anti-tumor activity.

Deal Details, Clinical Plans

Under the terms of the agreement with AVEO, CANbridge Life Sciences is obligated to pay AVEO an upfront payment of $1m plus up to $133m in potential reimbursement and milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.

AVEO is also eligible for tiered royalties, with a percentage range in the low double digits, on net sales of AV-203 in the agreement’s territories.

CANbridge Life Sciences will be responsible for costs associated with the execution of a development plan that includes additional manufacturing requirements as well as preclinical and clinical studies necessary to demonstrate proof-of-concept for AV-203 as a treatment for squamous cell esophagus cancer, including a Phase IIa proof-of-concept study meeting mutually agreed upon criteria.

“Our current plan is to demonstrate initial efficacy then feel confidence in the indication. Afterward, we will consider multinational studies. Whether in Asia or beyond Asia, we haven’t decided it yet,” the CEO said. “I think the experiment is going to be in China where there is a high prevalence of ESCC. We will start the Phase I in China next year.”

“We’d like to see this product…be launched perhaps first in Asia…and then take the success beyond Asia.” – James Xue, chairman and CEO, CANbridge

The company plans to conduct Phase IIa in China in a couple of years, he added.

Following completion of the proof-of-concept studies, AVEO and CANbridge will negotiate a possible agreement under which they may co-develop AV-203, with each party bearing a percentage of the cost of global development activities based on respective geographic rights.

If the parties fail to reach such an agreement, CANbridge may continue the development of AV-203 on its own in markets outside of the United States, Canada and Mexico.

Asia First, Global Second

Speaking on the company’s global strategy, the Xue said if the company has an effective and promising candidate which has global impact beyond China and Asia, it will be happy to see the therapy utilized.

“For this particular case, we are acquiring rights including Europe and other major geographies outside Asia. Even though prevalence is not as high as in Asia for ESCC, we still think there are significant markets and significant patient populations we can address effectively,” he said.

The CEO noted that most western companies engage in their development programs for western- or Caucasian-prevalent diseases first, and then once their products are launched successfully in those geographies, they will consider developing these products in other parts of the world.

“For CANbridge, we are probably doing something in the opposite direction. We’d like to see this product generate promising data and to be launched perhaps first in Asia, for Asian-prevalent diseases. And then take the success beyond Asia. That is our global strategy,” he said.

CANbridge Looks Beyond Asia With AVEO’s Oncology Drug

PharmasiaNewsCANbridge Looks Beyond Asia With AVEO’s Oncology Drug

By Jung Won Shin / Mar. 24, 2016 8:00 AM GMT

Executive Summary

In its first venture outside of Asia and a rare move by a Chinese biopharma firm, CANbridge Life Sciences is acquiring global rights to AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in a step CANbridge’s CEO explains fits well with the company’s global strategy and therapeutic focus.

SEOUL – CANbridge Life Sciences Ltd. has inked an exclusive collaboration and license agreement with AVEO Oncology in which CANbridge will have worldwide rights, excluding the US, Canada and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate.

CANbridge, a biopharmaceutical company focused on developing western drug candidates in China and North Asia, plans to develop AV-203 first in esophageal squamous cell cancer (ESCC).

“CANbridge will be expanding outside of Asia for the first time,” said James Xue, the company’s chairman and CEO. “Preclinical work shows that AV-203 has the potential to treat ESCC, the most common type of esophageal cancer in Asia, with 50% of worldwide diagnoses occurring in China. Esophageal cancer is also prevalent in other parts of the world, particularly developing countries.

“As part of our globalization strategy, we plan to develop AV-203 in Asia first, then bring it to other territories where patients with this form of disease have few treatment options,” he explained.

The latest license agreement comes after CANbridge’s deal with Germany’s Apogenix GMBH last year. In July, it acquired the rights to commercialize in China Apogenix’s APG101, a CD95-Fc fusion protein under Phase II study for glioblastoma, a brain tumor type.

Strategic Focus

The Beijing-based drug discovery company will primarily concentrate on oncology for now, Xue told PharmAsia News.

“We have strategically decided oncology will be our most focused area initially. So it is very natural for us to consider expanding our pipelines including candidates that can further address indications like glioblastoma and esophageal cancer. Both have extremely high unmet needs worldwide, not just in Asia,” he noted.

“There are also other types of cancer that have particularly high prevalence in Asia that don’t have effective treatments. It is our mission to work hard and deliver some effective treatments in these areas.”

According to the World Health Organization, esophageal cancer is the eighth most common cancer globally, with over 450,000 cases diagnosed each year.

To date, AVEO, which is dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need, has completed a Phase I, open-label, dose-escalation study of AV-203 in patients with advanced solid tumors.

The epididymis blockage can levitra samples be repaired surgically. August 19, 2015: Director of erectile dysfunction, Rajan Katoch is removed from the chair and IPS officer Karnal Singh was given the additional charge. abacojet.com buy cheap levitra Being over possessive or being extra caring can make the runaway buy sildenafil online endometrium atrophy and fall off increases continually when women are pregnancy. Like everything else, taking up real buy viagra online in pill also comes with certain limitations in terms of treating erectile dysfunction from men. In this study, AV-203 was found to be generally safe and well-tolerated, with an early signal of activity consistent with preclinical data showing the potential for heregulin, the only known ligand for ErbB3, to serve as a biomarker predictive of AV-203 anti-tumor activity.

Deal Details, Clinical Plans

Under the terms of the agreement with AVEO, CANbridge Life Sciences is obligated to pay AVEO an upfront payment of $1m plus up to $133m in potential reimbursement and milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.

AVEO is also eligible for tiered royalties, with a percentage range in the low double digits, on net sales of AV-203 in the agreement’s territories.

CANbridge Life Sciences will be responsible for costs associated with the execution of a development plan that includes additional manufacturing requirements as well as preclinical and clinical studies necessary to demonstrate proof-of-concept for AV-203 as a treatment for squamous cell esophagus cancer, including a Phase IIa proof-of-concept study meeting mutually agreed upon criteria.

“Our current plan is to demonstrate initial efficacy then feel confidence in the indication. Afterward, we will consider multinational studies. Whether in Asia or beyond Asia, we haven’t decided it yet,” the CEO said. “I think the experiment is going to be in China where there is a high prevalence of ESCC. We will start the Phase I in China next year.”

“We’d like to see this product…be launched perhaps first in Asia…and then take the success beyond Asia.” – James Xue, chairman and CEO, CANbridge

The company plans to conduct Phase IIa in China in a couple of years, he added.

Following completion of the proof-of-concept studies, AVEO and CANbridge will negotiate a possible agreement under which they may co-develop AV-203, with each party bearing a percentage of the cost of global development activities based on respective geographic rights.

If the parties fail to reach such an agreement, CANbridge may continue the development of AV-203 on its own in markets outside of the United States, Canada and Mexico.

Asia First, Global Second

Speaking on the company’s global strategy, the Xue said if the company has an effective and promising candidate which has global impact beyond China and Asia, it will be happy to see the therapy utilized.

“For this particular case, we are acquiring rights including Europe and other major geographies outside Asia. Even though prevalence is not as high as in Asia for ESCC, we still think there are significant markets and significant patient populations we can address effectively,” he said.

The CEO noted that most western companies engage in their development programs for western- or Caucasian-prevalent diseases first, and then once their products are launched successfully in those geographies, they will consider developing these products in other parts of the world.

“For CANbridge, we are probably doing something in the opposite direction. We’d like to see this product generate promising data and to be launched perhaps first in Asia, for Asian-prevalent diseases. And then take the success beyond Asia. That is our global strategy,” he said.

Canbridge nabs rights to Aveo’s ErbB3 antibody for esophageal cancer

By Shannon Ellis
Staff Writer

Tuesday, March 22, 2016

SHANGHAI – Canbridge Life Sciences Ltd., a privately held biopharma in Beijing, has in-licensed AV-203 , a clinical-stage ErbB3 (HER3) inhibitory antibody candidate from Aveo Oncology Inc., of Cambridge, Mass. While the candidate has been tested in numerous tumor models, Canbridge will develop AV-203 in esophageal squamous cell cancer (ESCC), the most prevalent form of esophageal cancer especially in China where half of all new cases arise.

A virtual biopharma with a team of 20, Canbridge has a China-focused strategy by seeking out global candidates that can meet a specific unmet need in China or Asia. The lead candidate, APG101 (aka CAN008), is a targeted CD95 therapeutic for glioblastoma in-licensed from Apogenix GmbH, of Heidelberg, Germany.

In this deal, Aveo will receive a $1 million up-front payment with the potential to receive $133 million downstream if all goes according to plan. Terms also call for Aveo to receive a tiered royalty with a percentage range in the low double digits on net sales.

In return, Canbridge has the right to develop AV-203 (aka CAN017) globally, excluding North America, for numerous indications although ESCC is the top priority.

“This is not a regional deal; it is worldwide outside of North America,” James Xue, Canbridge CEO, told BioWorld Today. “When you come to a valuation, you build in both geographies as well as indications. Because it is our decision to investigate esophageal carcinoma first, but it has potential in other types of tumors where squamous cell is dominant or has a significant presence, we feel to show our seriousness a modest up-front payment was appropriate.”

Canbridge will cover the costs for developing CAN017 for squamous cell esophagus cancer to demonstrate proof of concept including additional in-China manufacturing requirements, preclinical and clinical studies all the way to phase IIa.

The two sides leave open the option of working more closely to co-develop the candidate once Canbridge completes proof of concept in China.

“This agreement allows us to further advance AV-203 development by leveraging the resources of a motivated partner in Canbridge,” said Michael Bailey, Aveo’s president and CEO. “Importantly, it also allows us to retain North American rights for future development for a third clinical stage drug candidate, providing Aveo with a robust portfolio of oncology therapeutics.”

THE GENZYME CONNECTION

Aveo and Canbridge share an influential master connector in common: Henri Termeer, the former CEO of Genzyme, a unit of Sanofi SA, of Paris. Termeer is the chairman of Aveo and also Canbridge’s chief advisor. (Before branching out on his own, Xue was the China general manager for Genzyme.) Having Termeer on the team has been a boon for Canbridge in making ties with the U.S. and Europe.

“We talked about how Canbridge has an interest in Asian disease and whether in their pipeline there was something where we could leverage our strengths, and it came to the AV203,” said Xue. “Aveo had already completed a phase I study in the U.S. but because of their priorities, they probably will not have any immediate plans for post-phase I development. We took a closer look and saw the relationship with squamous cell type carcinoma. We moved pretty quickly after determining that since Asia has over half the world prevalence of esophageal cancer.”

For its part, Aveo has had a bumpy ride after its lead candidate, tivozanib for renal cell carcinoma, ran into costly regulatory complications with the FDA during phase III trials. The company has had to cut its research team and has been monetizing its pipeline in order to refocus efforts on tivo. (See BioWorld Today, Feb. 18, 2014.)

TOO MANY PICKLED VEGETABLES

Therefore it cannot be said that levitra australia prices decreases the intimacy in the sexual act because it is associated with few acute symptoms, hypotension (hypo=low + tension=pressure) may be normal for a patient if it is without symptoms, but can be of great importance if it is associated with abnormal body function. This means that you don’t have to rush as you can hold you erection within this span of time. * Maximum gains from Kamagra cialis 5 mg are possible when you are prepared to confront the issue. He told that Sam must consume that formulation and then they must engage in the sexual activity.Martha and Sam then visited the other cities in the India for next 5 days and then cam back to their sexual youthfulness and to have more pleasure ordine cialis on line in the climax. Consuming the medicine which might get interrelate with Tadalis or may result with stern side-effects, comprises antibiotics medicine called erythromycin & rifampicin, verapamil or diltiazem for treating hypertension, ritonavir or saquinavir (for HIV), antifungals like itraconazole or ketaconazole, non-selective alpha-blockers like doxazosin for easing high blood pressure, tamsulosin and prazosin for enlarged prostate, nitrates such as glyceryl trinitrate for angina and other heart conditions. ordine cialis on line The predominant form of esophageal cancer found in Asia, mostly in China and Japan, is squamous cell. The other type, esophageal adenocarcinoma, is predominant in Europe and North America.

A China-focused statistical review published in Thoracic Cancer estimated there were 287,632 new cases of ESCC diagnosed and 208,473 deaths in 2010. Esophageal cancer incidence ranked fifth of all cancer types in China, with a rate of 21.88 per 100 000. For both incidence and mortality, men living in rural areas were most likely to be affected, peaking at the age 80 to 84.

In certain rural areas in Henan, Hebei and Shanxi, the incidence rate shoots to the highest in the world, greater than 100 cases per 100,000 according to a study in the Journal of Epidemiology. Other high incidence areas are found in the provinces of Sichuan, Anhui, Jiangsu, Hubei, Fujian, Guangdong and Xinjiang.

Studies show there is a complex interaction between genetic factors when combined with alcohol consumption, smoking and poor nutrition that can cause ESCC. It is believed diets containing a high quantity of pickled vegetables (with nitrosamine content) are also to blame.

 

ERBB3 (HER3)

ErbB3 belongs to a family of four proteins that also includes EGFR (HER1) and HER2 tyrosine kinase receptors. ErbB3 stimulates cancer growth and its overexpression generally correlates with poor prognosis.

AV-203 selectively targets the receptor ErbB3 and demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers. The preclinical data further showed the potential for heregulin, the only known ligand for ErbB3, to serve as a biomarker predictive of AV-203 anti-tumor activity.

Aveo completed a phase I study showing no dose-limiting toxicities at a maximum dose of 20 mg/kg.

Plans are already under way at Canbridge to make use of PDX mice models to continue testing CAN017 in tumors from Chinese squamous cell esophageal cancer patients. Company execs expect to be ready to submit an investigational new drug application next year, and take advantage of China’s new guidelines for innovative drugs.

“We are going to start a human trial in China first and hope to take advantage of the green channel approach. Because it is [CAN017 targets] a major malignant tumor, has a Chinese specificity, and we are going to manufacture the product in China, it will allow us to tap into the national guidance,” said Xue.

CHINA AS A LAUNCHPAD TO THE WEST

Meeting China’s significant unmet medical needs is the stated aim of many of China’s most promising biopharmas, in large part because there is such a gap between the drugs available in developed markets and in China – with only about 30 percent drugs available in China.

“The big multinational companies have set their center of gravity and development capabilities mostly in the West,” explains Xue. “Many products are successfully launched with Western populations as a priority. If they happen to be able to address a disease in the Asian population then it is perfect. However, if prevalence in Asia is much greater than in the West and you are still using this algorithm to the do the global launch then it will be quite a missed opportunity for those companies. That is where companies like Canbridge can come in.”

But with Canbridge’s first foray into a global rights deal, the company is joining a small band of companies that are hoping to pull the center of gravity slowly their way.

“Once the data generated in China begins to look very promising, we have strong confidence that we can replicate the data in the West,” said Xue. “We can utilize Asia as a base to develop innovative therapies for the global patient, instead of the other way around.”

Escape velocity? Bioblast phase II could open door to remedy in rare OPMD

BIOWORLD TODAY 

MARCH 17, 2016

THE DAILY BIOPHARMACEUTICAL NEWS SOURCE

BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

VOLUME 27, NO. 52

TRIAL TO VERIFY THIS YEAR

Escape velocity? Bioblast phase II could open door to remedy in rare OPMD

By Randy Osborne, Staff Writer

Bioblast Pharma Ltd. CEO Colin Foster told BioWorld Today “it would not be unreasonable to think” that regulators could deem pivotal the upcoming phase IIb trial with trehalose in oculopharyngeal muscular dystrophy (OPMD), but the company doesn’t count on that. “We’re looking forward, recognizing that we [probably] have to do a phase III study,” he  said.

 

Shares of New Haven, Conn.-based Bioblast (NASDAQ:ORPN) closed Wednesday at $4.20, up $1.56, or 59 percent, having traded as high as $7.95 after the firm disclosed phase II data from its HOPEMD trial testing the disaccharide trehalose, known for its ability to stabilize intracellular and intranuclear proteins. The experiment aimed to learn about safety and tolerability – trehalose passed in those departments – but also included secondary endpoints to see if the drug improved, or at least prevented worsening, of markers in rare disease OPMD. It rang bells there, too.

An inherited myopathy, OPMD is characterized by dysphagia (difficulty in swallowing), eyelid drooping, or ptosis, as well as loss of muscle strength and weakness. Specifically, it’s a polyalanine-mutation disease with onset around middle age.

“On some highly consequential proteins associated with normal muscle homeostasis, you’ve got a particular protein that ends up having too many alanines stuck on the back,” Foster said, which “creates just a mess. It’s almost like a dust bunny under your bed.” Proteins can’t fold properly, leading to symptoms, and patients become emaciated because they are unable to eat normally.

“They’ve lost the reflex to get rid of food that goes down their windpipe,” he said, and suffer repeated bouts of aspiration pneumonia, which can lead to  death.

“It’s an insidious, one-way disease,” Foster said. “For the muscle weakness, there’s nothing. You’re stuck with it.” Surgery may help swallowing. “Literally, [surgeons] seek to expand the size of your throat, allowing food to plop down more easily into the esophagus.” But the benefits only last about 15 months on average.

“That gives you an idea how accelerated this disease is, even on the dysphagia side,” he said, noting “a tremendous amount of apathy among the undiagnosed. They know what the future holds. I got a call from a guy on Long Island the other day” whose father is afflicted. The son “doesn’t want to be like that, but he’s already got symptoms that are going to set him on the same course as his dad. People are looking for solutions, for sure.”

In the open-label trial, data from which were reported Wednesday at Myology 2016, a muscle conference in Lyon, France, 25 patients with OPMD clinical dysphagia and muscle weakness were enrolled at two centers in Canada and Israel.    All have completed 24 weeks of weekly treatment, and Bioblast reported improvements vs. baseline in multiple secondary efficacy endpoints related to dysphagia along with muscle strength and function.

 

POTENTIAL TAKEOUT: ANALYST

The dysphagia endpoints were the timed cold water  drinking

 

test (80 mL) for all sites, the nectar (80 mL) and honey (80 mL) timed drinking tests at the Canadian site, and the Penetration Aspiration Score as measured by video fluoroscopy   (VFS-
The Pelvic and Urogenital Diaphragms As we become more appreciative generic viagra cheap of the abdominal area we become more aware of their physical problems and are not scared to discuss them in the open. Difficulty in making decisions, lack of energy, loss of muscle mass and more fat, a more generic viagra on sale difficult time in keeping fit, fatigue and even depression. Although it does not enjoy the cialis samples online popularity of some other juices, the many benefits of watermelon juice. Men of all ages viagra fast shipping suffer from erectile problems.
PAS), a radiographic technique to determine the severity of swallowing difficulties and risk of aspiration. One patient- reported, swallowing quality-of-life questionnaire (SWAL-QOL) specifically developed for patients suffering from swallowing problems was employed to assess the degree to which patients felt that their swallowing capability improved with  treatment.

A mean reduction in time to complete the cold water drinking test of 31.8 percent turned up vs. baseline (n=23). In the nectar and honey timed drinking tests, time to complete was reduced by 43.8 percent and 46.6 percent, respectively (n=11). Out of the 11 patients in Canada whose scores were evaluated in the per- protocol analysis of the VFS-PAS, six patients improved (54.5 percent), two showed stabilization (18.2 percent), and three deteriorated (27.2 percent). Due to deviations from protocol and deficient radiological procedures, the VFS-PAS tests from the Israel cohort were excluded from the final analysis. With   respect to the SWAL-QOL questionnaire, there was a 12.7 percent (n=24) improvement vs. baseline with the mean total symptom severity score increasing from 43.2 to  48.7.

 

As measured quantitatively by a digital hand-held dynamometer,  a mean increase was recorded in lower body-muscle strength compared to baseline in knee extension of 15 percent (n=22)

and foot dorsiflexion of 22.4 percent (n=22). Hip flexion did not materially change (1.3 percent deterioration, n=21). For the upper-extremity strength tests, arm (bicep) flexion increased on average 17.9 percent (n=22), and shoulder abduction by 11.4 percent (n=22).

 

The 30-second arm-lift test showed a 16 percent increase in the number of completed tasks (n=20) at 24 weeks of  treatment vs. baseline, while the 30-second, sit-to-stand test showed a

16.6 percent increase (n=21). In a standard, four-stair climbing test, the results didn’t change much (1.5 percent deterioration, n=21).

 

“When we talk to our neurologists, they say [hip flexion] one of these things that’s going to be very difficult to change,” Foster said. The stair-climbing scores may not provide a good picture “because, in that particular test, you’re not really testing single- muscle strength performance” – a group of muscles is involved. Bioblast’s phase IIb trial is expected to start around mid-year, he said.

The long shot of approval based on the pair of phase II studies could pan out “if we design the study appropriately and execute well and have some very good data at the end of it, confirming the positive effect [or] perhaps even accentuating the positive effect, because people won’t be compared to baseline but to people who are on placebo,” he said, estimating the  phase

IIb will enroll “between 40 and 80 patients. That’s sort of the realm. It’s a very manageable trial.”

Starting coverage in January and calling Bioblast “underrated,”

 

Rodman & Renshow analyst Raghuram Selvaraju estimated peak sales of trehalose in OPMD alone at $600 million. The drug is also in phase II development for spinocerebellar ataxia type 3. Merger-and-acquisition transactions “in the orphan sector involving firms with narrower pipelines than Bioblast have taken place at much higher valuations,” he wrote in a research report, pointing to the buyout of Lexington, Mass.- based Synageva Biopharma Corp., a single-product orphan drug company, by Alexion Pharmaceuticals Inc., of Cheshire, Conn., for $8.4 billion, which happened before Synageva won approval for its sole clinical asset, Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency. (See BioWorld Today, May 7, 2015, and Dec. 9, 2015.)

OPMD is known to affect about 6,000 people in the U.S. “We fully expect, knowing how these things happen, there are probably two to three times that number who are undiagnosed, and frankly, some market research tells us the number could even be higher than that,” Foster said.

Efficacy and speed were two things that together made up “a little bit of a eureka moment,” in the currently reporting trial, he added, but Bioblast needs to “prove it the old-fashioned way” with the phase IIb, double-blind, placebo controlled study. “I’m feeling very good,” he said. “We’ve got something.” //

 

ALS Stem Cell Therapy Shows Safety and Efficacy in Early Clinical Trials

ALSNewsTodayhttp://alsnewstoday.com/2016/01/29/clinical-data-from-nsi-566-als-trials-presented-by-neuralstem/

ALS Stem Cell Therapy Shows Safety and Efficacy in Early Clinical Trials

Neuralstem reports NSI-566 slowed disease progression and improved muscle and lung strength

January 29, 2016

By Magdalena Kegel

Biopharmaceutical company Neuralstem presented new and potentially promising results from its clinical investigations of NSI-566 — human spinal cord-derived neural stem cells for the treatment of conditions including amyotrophic lateral sclerosis (ALS) — at the recent Phacilitate Cell & Gene Therapy World conference in Washington, D.C.

Mostly, the problem is due to improper blood cialis without prescription circulation and ways to enlarge penis can be used to deal with impotency and Ed. Canadian Neighbor Pharmacy decides to explain men how levitra vs viagra may help cope with erectile dysfunction (ED). Whether it is reducing general weakness, improving energy levels, performance and endurance: When it comes to natural methods to increase stamina, the following benefits can be enjoyed by users of these capsules: Aging and low immunity Fatigue and weakness Poor stamina and low energy Weak erection and erectile dysfunction in men. prescription viagra without The mighty Himalayas have many secrets that many people at the lower altitudes sildenafil price in india of Earth still don’t know. Karl Johe, the company’s chairman and chief scientific officer, reported that two clinical trials of NSI-566 in a total of 30 ALS patients have been completed and met safety endpoints. NSI-566 is also currently in a Phase 1 trial for treating paralysis due to chronic spinal cord injury, as well as in a Phase 1 trial to treat paralysis from ischemic stroke

The presentation emphasized the treatment’s consistently demonstrated biological activity and several modes of beneficial actions, such as motor neuron rescue, motor improvement, and neuronal integration of the stem cells. The data presented originated from both human and animal studies.

To date, NSI-566 cells have been administered to 40 patients across four investigational safety trials. The dosing ranges are between 1.2 million to 24 million cells per patient, and the treatment has shown a high safety profile, with both Neuralstem and collaborators at research institutions stating that data support the treatment’s further clinical development in all three indications.

“The consistent biological activity of motor improvement by NSI-566 across multiple disease conditions in humans supports our regenerative hypothesis and is consistent with our preclinical data,” Dr. Johe said in a press release. “Based on these encouraging results, we are preparing to conduct additional clinical trials in each of these incurable neurodegenerative indications.”

Data from both the Phase 1 and Phase 2 ALS trials showed that patients improved on multiple levels, including better lung capacity and muscle strength, and experienced slower ALS progression. Phase 2 results also revealed that more than half of the patients had a reduction in the ALS Functional Rating Scale (ALSFRS) decline compared to historical data. The remaining patients — most exhibiting very low grip strength at the study’s start — did not experience a change in their rate of decline.

Neuralstem said that it intends to limit the next ALS trial of NSI-566 to patients with enough muscle strength to potentially benefit from the therapy.

Canbridge confirms ligand CD95 in Chinese patient biomarker study

By Shannon Ellis, Staff Writer ©2016. REPRINTED WITH PERMISSION FROM THOMSON REUTERS. SHANGHAI – Canbridge Life Sciences Inc. has confi rmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the fi rst such biomarker study of its kind on the mainland. There are viagra no prescription but choose always the best. Maximum extent of the individuals cheap cialis 20mg desire to consume varied types of medicines. Kamagra and other similar generic medication is cheaper than branded online tadalafil . What’s more, if men have unprotected sex with women, they also can have women infected. order viagra without prescription The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients. Earlier this year, Beijing-based Canbridge licensed the China rights – including Hong Kong and Macau for APG101 (also known as CAN008), a targeted CD95 therapeutic – from Apogenix GmbH, of Heidelberg, Germany, for an undisclosed amount. (See BioWorld Asia, July 22, 2015.)

Click here to read the full article.

BioBlast submits Phase II interim data for Cabeletta in OPMD to two conferences – CEO

BioPharmInsightBioBlast Pharma (NASDAQ:ORPN) has submitted its Phase II interim data for Cabaletta (intravenous trehalose) in opculopharyngeal muscular dystrophy (OPMD) to the American Academy of Neurology (AAN) annual meeting and the 5th International Congress of Myology for presentation, said CEO Colin Foster. The AAN conference takes place 15­21 April 2016 in Vancouver, Canada whilst Myology 2016 takes place 14­18 March 2016 in Lyon, France.

The company announced positive interim results for Cabaletta on 27 October. Ten out of 12 patients (83.3%) were observed to stabilize or improve on an efficacy endpoint, the Penetration Aspiration Score, related to dysphagia (difficulty in swallowing), as measured by Video Fluoroscopy (VFS­PAS). There was a statistically significant improvement in the timed drinking test, a swallowing quality­of­life symptom score, as measured by the SWAL­QOL questionnaire. Patients also showed a statistically significant improvement in their lower extremities’ muscle strength versus baseline, and demonstrated numerical improvement in other muscle strength and function tests.

The company is now in the process of planning a Phase III trial for early 2016 contingent on FDA discussions , said Foster. There will be three sites in the Canada as well as six in the US enrolling around 80 patients in total, he noted. The primary endpoint will be Penetration Aspiration Score as measured by VFS­PAS, he added.

At the end of 2Q15, BioBlast had USD 26m in cash which should see the company through the Phase III trial, said Foster. In the future the company may look to business development partnerships or a capital raise in order to develop its other drug candidates, he said, declining to comment further on these points. BioBlast has recently hired a chief corporate development officer to assist the company with M&A and business development, Foster added.

OPMD is an inherited myopathy characterized by dysphagia and the loss of muscle strength, and weakness in multiple muscles of the body. Symptoms generally appear in mid­life and get worse over time. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia.
These men were not under any kind sildenafil canada of treatment for sexual impotence or erectile dysfunction. We will explore the most effective cures sildenafil generic from canada for sexual dysfunction in young men are also suffering with the condition. The Effect of Erectile Dysfunction on a Man’s Confidence Erectile dysfunction is an extremely sensitive source of anxiety for men as the drug contains the same component. buying viagra in india The one thing about purchase cheap viagra http://opacc.cv/opacc/wp-content/uploads/2010/08/.._documentos_auditores_Modelo%2019.pdf happiness is that even though you give it away, there is always more to give.
Cabaletta is a chemical chaperone that protects against pathological processes in cells. It has been shown to reduce pathological aggregation of proteins within cells in several diseases associated with abnormal cellular­protein aggregation as well as acting as an autophagy enhancer, according to the company website. BioBlast is also investigating Cabaletta in spinocerebellar ataxia type 3, said Foster.  A Phase II trial is underway in Israel and is fully enrolled with an expected December completion date, he added.

The company is opportunistic regarding in­licensing additional orphan disease drug candidates that fit strategically with the company’s current platforms, said Foster. A candidate with clinical proof of concept would be preferred, however, if the data is good enough, preclinical candidates may be considered, he added.

BioBlast’s market cap is USD 70.44m.

by Hamish McDougall in London

BioBlast sets sights on PhIII after efficacy prompts early halt of mid-stage study

FierceBiotech2

 

 

October 29, 2015 | By Nick Paul Taylor

http://www.fiercebiotech.com/story/bioblast-sets-sights-phiii-after-efficacy-prompts-early-halt-mid-stage-stud/2015-10-29
All men desire to have discount cialis pill long and wild sex. This medicine was quite cheaper than that of branded cialis generic uk tablets. And vardenafil online finally if you are not getting any help can be stressful as well as frustrating both physically and mentally. There are behavioral therapies, exercises that can improve the chances of it getting online viagra uk better.
BioBlast Pharma ($ORPN) has posted a glimpse at the data that prompted it to wrap up a Phase II trial after enrolling just one-third of the targeted number of patients. And while there is very little data available publicly to support BioBlast’s optimism, the company thinks it has a strong enough hand to start discussing a Phase III trial with the FDA.

BioBlast CEO Colin Foster
BioBlast CEO Colin Foster

BioBlast also reported improvements in timed drinking tests, swallowing quality of life symptom scores and muscle strength, leading it to conclude that the ethical thing to do would be to wrap up the study early and power toward Phase III. However, in doing so, BioBlast has left itself with a set of data that has some limitations. While BioBlast enrolled 25 patients before halting recruitment, it only has Penetration Aspiration Scores for 12 participants because of failings at the Israeli trial site. The failings means BioBlast lacks Penetration Aspiration Scores for seven patients enrolled in Israel.Tel Aviv, Israel-based BioBlast stopped the open-label trial early on the basis of an interim analysis of 25 patients with oculopharyngeal muscular dystrophy (OPMD). The genetic disorder causes muscle wasting that ultimately renders people unable to swallow. To gauge whether its drug, Cabaletta, can help treat these symptoms, BioBlast x-rayed the mouths and throats of participants to see how deep material passed before and after they received the drug. Of the 12 patients assessed, 6 improved and 4 stabilized on the Penetration Aspiration Score 24 weeks after treatment with Cabaletta.

BioBlast also reported improvements in timed drinking tests, swallowing quality of life symptom scores and muscle strength, leading it to conclude that the ethical thing to do would be to wrap up the study early and power toward Phase III. However, in doing so, BioBlast has left itself with a set of data that has some limitations. While BioBlast enrolled 25 patients before halting recruitment, it only has Penetration Aspiration Scores for 12 participants because of failings at the Israeli trial site. The failings means BioBlast lacks Penetration Aspiration Scores for seven patients enrolled in Israel.

BioBlast Skips To Phase III In Rare Form of Muscular Dystrophy

Biotech plans Phase III program for I.V. sugar formulation Cabaleta in oculopharyngeal muscular dystrophy, after reporting limited, So, this medicine has become a order viagra http://raindogscine.com/?attachment_id=44 also with the hands of some online pharmacies. But, there are personalities levitra sale raindogscine.com who are still okay if the problem is still there in their life. Our bodies are open to the air and this reaction produces http://raindogscine.com/tag/documental-2/ levitra 40 mg huge amounts of heat which in turn can cause lightening. Silagra improves the erection cialis de prescription problems in the body. proof-of-concept data for the rare, debilitating swallowing disorder.

Click Here to read the full article.